Eli Lilly and Incyte's Olumiant has secured the first FDA approval for a systemic drug to treat alopecia areata, an autoimmune condition causing patchy hair loss that affects more than 700,000 ...

Eli Lilly and Incyte's JAK inhibitor Olumiant reduced the risk of death by 13% in hospitalised COVID-19 patients when added to other drugs, according to new results from the UK RECOVERY trial.

Analysts have set 12-month price targets for Incyte, revealing an average target of $73.69, a high estimate of $97.00, and a ...

The field of atopic dermatitis (AD) has been receiving great interest over the last few years with the approvals of both oral ...

Key drugs from Johnson & Johnson and Eli Lilly ... Eli Lilly revs up immunology engine as Olumiant cruises toward coveted alopecia green light "This trial supports the growing body of data showing ...